The BIOFIRE® SPOTFIRE® Respiratory Solution: A Custom Fit for Your Clinic’s Needs
The benefit of low-plex and high-plex testing options on one platform
Prior to the COVID-19 pandemic, respiratory tract infections were among the top three diagnoses in point-of-care settings—they’re one of the main reasons patients seek care.1 In the era of COVID-19, now more than ever, patients want certainty about what’s causing their respiratory illness.
Unfortunately, rapid antigen tests may not provide the certainty patients are looking for. Rapid antigen tests generally only test for one to three pathogens and they are less sensitive than molecular tests, leaving patients with uncertainty about the accuracy of negative results. When patients have taken the time and effort to visit a clinic for care, they want a more definitive answer than “You probably don’t have COVID-19 or influenza. You likely have some other viral infection.”
Data from BIOFIRE® Syndromic Trends (Trend) demonstrate that numerous respiratory pathogens have circulated throughout the past year. At times in 2022, rhinovirus/enterovirus and respiratory syncytial virus (RSV) greatly outpaced coronaviruses, including SARS-CoV-2.2